South Korea · Delayed Price · Currency is KRW J2KBIO Statistics
Total Valuation
J2KBIO has a market cap or net worth of KRW 45.67 billion. The enterprise value is 37.40 billion.
| Market Cap | 45.67B |
| Enterprise Value | 37.40B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
J2KBIO has 5.85 million shares outstanding. The number of shares has increased by 2.48% in one year.
| Current Share Class | 5.85M |
| Shares Outstanding | 5.85M |
| Shares Change (YoY) | +2.48% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 62.10% |
| Owned by Institutions (%) | n/a |
| Float | 2.21M |
Valuation Ratios
The trailing PE ratio is 11.30.
| PE Ratio | 11.30 |
| Forward PE | n/a |
| PS Ratio | 1.24 |
| PB Ratio | 1.35 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | 16.92 |
| P/OCF Ratio | 14.64 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.13, with an EV/FCF ratio of 13.86.
| EV / Earnings | 9.28 |
| EV / Sales | 1.02 |
| EV / EBITDA | 6.13 |
| EV / EBIT | 8.31 |
| EV / FCF | 13.86 |
Financial Position
The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.74 |
| Quick Ratio | 2.86 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.17 |
| Debt / FCF | 0.39 |
| Interest Coverage | 101.01 |
Financial Efficiency
Return on equity (ROE) is 12.35% and return on invested capital (ROIC) is 16.85%.
| Return on Equity (ROE) | 12.35% |
| Return on Assets (ROA) | 7.27% |
| Return on Invested Capital (ROIC) | 16.85% |
| Return on Capital Employed (ROCE) | 12.85% |
| Weighted Average Cost of Capital (WACC) | 6.57% |
| Revenue Per Employee | 681.93M |
| Profits Per Employee | 74.61M |
| Employee Count | 54 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 6.80 |
Taxes
In the past 12 months, J2KBIO has paid 471.85 million in taxes.
| Income Tax | 471.85M |
| Effective Tax Rate | 10.48% |
Stock Price Statistics
The stock price has decreased by -26.80% in the last 52 weeks. The beta is 0.43, so J2KBIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -26.80% |
| 50-Day Moving Average | 8,396.20 |
| 200-Day Moving Average | 8,574.30 |
| Relative Strength Index (RSI) | 33.61 |
| Average Volume (20 Days) | 321,309 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, J2KBIO had revenue of KRW 36.82 billion and earned 4.03 billion in profits. Earnings per share was 691.15.
| Revenue | 36.82B |
| Gross Profit | 14.68B |
| Operating Income | 4.50B |
| Pretax Income | 4.50B |
| Net Income | 4.03B |
| EBITDA | 6.10B |
| EBIT | 4.50B |
| Earnings Per Share (EPS) | 691.15 |
Balance Sheet
The company has 9.33 billion in cash and 1.06 billion in debt, with a net cash position of 8.27 billion or 1,413.60 per share.
| Cash & Cash Equivalents | 9.33B |
| Total Debt | 1.06B |
| Net Cash | 8.27B |
| Net Cash Per Share | 1,413.60 |
| Equity (Book Value) | 33.90B |
| Book Value Per Share | 5,804.03 |
| Working Capital | 16.49B |
Cash Flow
In the last 12 months, operating cash flow was 3.12 billion and capital expenditures -421.69 million, giving a free cash flow of 2.70 billion.
| Operating Cash Flow | 3.12B |
| Capital Expenditures | -421.69M |
| Depreciation & Amortization | 1.60B |
| Net Borrowing | -277.61M |
| Free Cash Flow | 2.70B |
| FCF Per Share | 461.51 |
Margins
Gross margin is 39.86%, with operating and profit margins of 12.23% and 10.94%.
| Gross Margin | 39.86% |
| Operating Margin | 12.23% |
| Pretax Margin | 12.22% |
| Profit Margin | 10.94% |
| EBITDA Margin | 16.56% |
| EBIT Margin | 12.23% |
| FCF Margin | 7.33% |
Dividends & Yields
This stock pays an annual dividend of 250.00, which amounts to a dividend yield of 3.20%.
| Dividend Per Share | 250.00 |
| Dividend Yield | 3.20% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 29.69% |
| Buyback Yield | -2.48% |
| Shareholder Yield | 0.72% |
| Earnings Yield | 8.82% |
| FCF Yield | 5.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
J2KBIO has an Altman Z-Score of 6.86 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.86 |
| Piotroski F-Score | 5 |